Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study…
At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at…
In a discussion on cancer science, Wassim Mchayleh, MD, explores the role of Minimal Residual…
By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI…
By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with…
By. Neil Carleton, MD Date. 12/07/2023 In the interview with Neil Carleton, MD, the discussion revolved…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in…
By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…